Celgene Corporation, once traded on NASDAQ under the ticker symbol CELG, was a prominent biopharmaceutical company focused on developing innovative therapies for cancer and inflammatory diseases. Founded in 1986, the company gained substantial recognition for its groundbreaking treatments, particularly in hematology and oncology.
One of Celgene's flagship products was Revlimid (lenalidomide), designed to treat multiple myeloma and certain types of lymphoma. The drug received approval in multiple jurisdictions and became a cornerstone of treatment for these conditions due to its effectiveness and manageable side effect profile. Another significant product was Pomalyst (pomalidomide), which was approved for use in patients who had been treated with other therapies.
In addition to its oncology portfolio, Celgene also developed therapies for inflammatory disorders, including Otezla (apremilast), a treatment for psoriasis and psoriatic arthritis. This diversification allowed the company to tap into different segments of the biotech market, positioning it as a leader in both oncology and inflammation.
In January 2019, Celgene was acquired by Bristol-Myers Squibb (BMY) in a deal valued at approximately $74 billion. This acquisition aimed to enhance Bristol-Myers Squibb's oncology pipeline by integrating Celgene's robust portfolio of cancer therapies and expanding its research capabilities. The merger was seen as a strategic move to boost long-term growth and market competitiveness in the biopharmaceutical landscape.
Effective from the acquisition date, Celgene's operations were integrated into Bristol-Myers Squibb, leading to the cessation of its trading on NASDAQ. The legacy of Celgene continues within Bristol-Myers Squibb, as its innovative therapies remain crucial in the company’s commitment to addressing unmet medical needs in oncology and beyond.
As of October 2023, Celgene Corporation (NASDAQ: CELG) remains a significant player in the biopharmaceutical industry, primarily known for its innovative therapies in oncology and immunology. Although Celgene was acquired by Bristol-Myers Squibb (BMY) in November 2019, its legacy continues to influence market sentiment and investment strategies.
To provide market advice for potential investors eyeing Celgene, it's critical to consider the company's drug portfolio and ongoing development pipeline. Celgene's most renowned products, including Revlimid and Pomalyst, have contributed significantly to revenue streams, but their patent expirations pose potential risks. The ongoing management of these drugs in a competitive generics landscape will be pivotal for maintaining market share.
Investors should also evaluate Celgene's role within Bristol-Myers Squibb. The integration of Celgene's assets has augmented Bristol-Myers' oncology capabilities, notably in multiple myeloma and hematological cancers. Consequently, any investment consideration should account for Bristol-Myers' broader strategic vision and financial health post-acquisition.
On the innovation front, Celgene’s pipeline shows promise, with several candidates in late-stage clinical trials. For example, the development of novel therapies utilizing CAR-T cell technology and combinations with immune checkpoint inhibitors could offer substantial upside potential. Monitoring FDA approvals and market launches for these candidates will be crucial for forecasting growth.
In terms of valuation, prospective investors should analyze earnings reports, assess the price-to-earnings (P/E) ratio, and evaluate comparisons with industry peers. The overall market conditions, alongside changes in healthcare regulations and reimbursement models, will also influence performance.
In summary, while Celgene itself is no longer an independent entity, its influence as part of Bristol-Myers Squibb remains vital. Investors should adopt a cautious yet optimistic approach, keeping abreast of strategic developments, earnings, and industry trends.
* MWN AI Summary and Analysis is based on asking OpenAI to summarize and analyze the company and stock symbol.
Celgene is a biopharmaceutical firm that discovers, develops, and markets therapeutics for the treatment of cancer and immunological diseases. Celgene markets Thalomid and Pomalyst to treat multiple myeloma and Revlimid, a less toxic thalidomide derivative, to treat myelodysplastic syndromes, multiple myeloma, and mantle cell lymphoma. Acquisitions have brought MDS drug Vidaza, T-cell lymphoma drug Istodax, and cancer drug Abraxane. The firm's first immunology drug, Otezla, was approved in the U.S. in 2014. Recent acquisitions of Juno and Impact bring additional drugs for Celgene's blood cancer pipeline.
Quote | Celgene Corporation (NASDAQ:CELG)
Last: | $ |
---|---|
Change Percent: | 0.88% |
Open: | $101.11 |
Close: | $101.86 |
High: | $102.02 |
Low: | $101.11 |
Volume: | 2,053,419 |
Last Trade Date Time: | 12/31/1969 07:00:00 pm |
News | Celgene Corporation (NASDAQ:CELG)
In this clip from "The Pharma & Biotech Show" on Motley Fool Live , recorded on Feb. 2 , Motley Fool contributor Brian Orelli analyzes Gilead 's (NASDAQ: GILD) earnings report and discusses why the biotech giant could see fairly low revenue growth or even see earnings dr...
Bristol Myers Squibb has an impressive portfolio of assets and strong financials. The company has recently wrapped up large acquisitions. The company is focused on redeveloping its portfolio and expects a massive increase in revenue from new businesses. Going forward, we expect sh...
Message Board Posts | Celgene Corporation (NASDAQ:CELG)
Subject | By | Source | When |
---|---|---|---|
Better Buy: Celgene vs. Gilead Sciences | BottomBounce | investorshub | 10/24/2020 12:38:18 PM |
Sorry, dont know | patrickjishere | investorshub | 02/18/2019 10:31:14 PM |
Do you or anyone here know the tax | rosemountbomber | investorshub | 02/18/2019 10:08:04 PM |
Advances in Cancer Drugs Fuel Deal -- WSJ | TheFinalCD | investorshub | 01/04/2019 2:09:31 PM |
Yep, I like $BMY and the deal. | patrickjishere | investorshub | 01/03/2019 7:24:29 PM |
MWN AI FAQ **
Recent developments impacting Celgene Corporation include the FDA's approval of its multiple myeloma drug Abecma and advancements in its other therapies, while ongoing integration with Bristol-Myers Squibb post-merger continues to shape its drug pipeline and regulatory strategy.
Celgene Corporation's financial performance has been negatively impacted by increased competition in the biotechnology industry, which has pressured its market share and revenue growth, particularly in areas where new therapies have emerged to challenge its existing products.
Following its acquisition by Bristol-Myers Squibb, Celgene Corporation's growth prospects are bolstered by enhanced R&D capabilities and an expanded product portfolio, potentially strengthening its market position in oncology and immunology sectors.
Celgene Corporation is addressing pricing pressures and market access challenges for its key therapies by engaging in value-based pricing strategies, enhancing patient access programs, and collaborating with payers to demonstrate the clinical benefits and cost-effectiveness of its medications.
** MWN AI Questions are based on asking OpenAI to ask and answer four questions about the company and stock symbol.
News, Short Squeeze, Breakout and More Instantly...
Celgene Corporation Company Name:
CELG Stock Symbol:
NASDAQ Market:
In this clip from "The Pharma & Biotech Show" on Motley Fool Live , recorded on Feb. 2 , Motley Fool contributor Brian Orelli analyzes Gilead 's (NASDAQ: GILD) earnings report and discusses why the biotech giant could see fairly low revenue growth or even see earnings dr...
What coronavirus? Amgen 's (NASDAQ: AMGN) latest set of quarterly figures, delivered Tuesday, showed growth in the company's fundamentals during a challenging time for companies across all economic sectors. The veteran biotech company booked revenue of nearly $6.21 billion in the second qu...
It's scary out there right now for investors, with wild market swings and a lot of negative news coming out of quarterly reports. There is one sector, however, that will survive and likely thrive despite the coronavirus pandemic shutdown -- healthcare. That said, investors shouldn't head for jus...